CAPE improves obesity-related steatosis, at least in part, by inhibiting BSH activity through the gut microbiota–bile acid–farnesoid X receptor (FXR) pathway [59]. The gene discussed is NR1H4; the disease is obesity due to melanocortin 4 receptor deficiency.